[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JPS6016928A - Ointment - Google Patents

Ointment

Info

Publication number
JPS6016928A
JPS6016928A JP12388083A JP12388083A JPS6016928A JP S6016928 A JPS6016928 A JP S6016928A JP 12388083 A JP12388083 A JP 12388083A JP 12388083 A JP12388083 A JP 12388083A JP S6016928 A JPS6016928 A JP S6016928A
Authority
JP
Japan
Prior art keywords
ointment
fine powder
natural radioactive
tissue
radioactive minerals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP12388083A
Other languages
Japanese (ja)
Inventor
Nobuharu Irie
煎江 伸玄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP12388083A priority Critical patent/JPS6016928A/en
Publication of JPS6016928A publication Critical patent/JPS6016928A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To provide an ointment preparation containing fine powder of natural radioactive minerals, and capable of promoting the metabolism and improving the absorptivity or penetrability of the drug component of the ointment into the living tissue. CONSTITUTION:The objective ointment contains 1-5wt% fine powder of natural radioactive minerals (e.g. fergusonite, monazite, etc.). The living tissue of the applied part is stimulated by the radiation radiated from the fine powder of the natural radioactive minerals, and the metabolism of the tissue is accelerated. Accordingly, the absorptivity or penetrability of the drug component of the ointment into the tissue can be improved, the development of the drug effect can be promoted, and the diseases can be cured rapidly.

Description

【発明の詳細な説明】 この発明は外皮用薬として皮膚に塗布する軟こうの改良
に関するもので、天然放射性鉱物の微粉末を混合(混入
)したことを特徴としている。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an improvement in an ointment to be applied to the skin as a dermatological drug, and is characterized by incorporating (mixing) fine powder of natural radioactive minerals into the ointment.

この発明に係る軟こうによれば、天然放射性鉱物の微粉
末から放射される放射線によって、軟こう塗布部の生体
組織が刺激されて、新陳代謝が促進さnlこれにより軟
こう中の薬剤の生体組織への吸収性ないしは浸透性が高
められるので、薬効が早く、疾患等の治ゆ速度が早いと
いうきわめて有用な効果が奏される。
According to the ointment of the present invention, the radiation emitted from the fine powder of natural radioactive minerals stimulates the living tissue in the ointment area, promoting metabolism, thereby causing the drug in the ointment to be absorbed into the living tissue. Since the permeability or permeability is increased, extremely useful effects such as faster medicinal efficacy and faster healing of diseases etc. can be achieved.

この発明の軟こうにおける天然放射性鉱物としては、一
般には、フェルグソン石、モナズ石、苗木石、エナ石、
カルノー石などを用いることができる。
Natural radioactive minerals in the ointment of this invention generally include fergusonite, monazite, saplingite, enastone,
Carnot stone or the like can be used.

またこの軟こうにおける天然放射性鉱物の微粉末の混合
比率は、軟こうのコストアップの抑制やその1日数回塗
布の用法等の点から、一般には、1〜5重量%にするこ
とができる。
In addition, the mixing ratio of the fine powder of natural radioactive minerals in this ointment can generally be 1 to 5% by weight from the viewpoint of suppressing the cost increase of the ointment and using the ointment by applying it several times a day.

次にこの発明に係る軟こうの効果を実験例の点から明ら
かKする。
Next, the effects of the ointment according to the present invention will be clearly demonstrated from the experimental examples.

〔実験例1〕 (株)近江兄第社製軟こう(商品名:メンターム>Cd
t−カンフル 9.6096、l−メントール 1.3
5 %、ユーカリ油 1.3%、サリチル酸メチル 0
.22 %、白色ワセリン 66.44%、黄色ワセリ
ン 16.63%)と、と几にフェルグソン石(酸化ラ
ジウム 5.90 %、酸化トリウム 1.2996、
酸化ニオビウム 41.39%、酸化イツトリウム38
.29 %、その他 13.13%)の微粉末を1.5
重量%混合した軟こうとを、それぞれほぼ同等のすり傷
に3回/日の割合で塗布したところ、前者の周知の軟こ
うの場合には、5日後には九が完全におさまり、かさぶ
たができたが、後者のこの発明の軟こうの場合には、早
くも3日目に上記のような状態になった。
[Experiment Example 1] Soft plaster manufactured by Omi Anidai Co., Ltd. (Product name: Mentam>Cd
t-camphor 9.6096, l-menthol 1.3
5%, eucalyptus oil 1.3%, methyl salicylate 0
.. 22%, white petrolatum 66.44%, yellow petrolatum 16.63%), and fergusonite (radium oxide 5.90%, thorium oxide 1.2996%,
Niobium oxide 41.39%, Yttrium oxide 38%
.. 29%, other 13.13%) fine powder to 1.5%
When ointment mixed with a weight percent mixture was applied to approximately the same level of abrasions three times a day, in the case of the former well-known ointment, the ointment completely subsided and a scab formed after 5 days. However, in the case of the latter ointment of this invention, the above condition occurred as early as the third day.

〔実施例1〕 (株)大塚製薬工場製軟こう(商品名:オロナインH軟
こう)(グルコン酸クロールヘキシジン液(20%) 
1 %、基剤 99%)と、これに〔実験例I〕におけ
るものと同一のフェルグソン石の微粉末を2重量%混合
した軟こうとを、そnぞれほぼ同等の軽いやけど部に3
回/日の割合で塗布1〜たところ、前者の軟こうの場合
には7日後にほぼ完治の状態になったのに対し、後者の
軟こうの場合には5日後に完治の状態になった。
[Example 1] Otsuka Pharmaceutical Factory Co., Ltd. ointment (trade name: Oronine H ointment) (chlorhexidine gluconate solution (20%)
1%, base material 99%) and 2% by weight of the same fine powder of fergusonite as in [Experimental Example I] were mixed into approximately the same light burn areas for 3 to 3 hours.
When the ointment was applied once per day, the former ointment was almost completely cured after 7 days, while the latter ointment was completely cured after 5 days.

特許出願人 煎 江 伸 玄 代理人 井上英朗Patent applicant Nobugen Sene Agent Hideaki Inoue

Claims (2)

【特許請求の範囲】[Claims] (1)天然放射性鉱物の微粉末を混合してなる軟、こう
(1) A soft product made by mixing fine powder of natural radioactive minerals.
(2)天然放射性鉱物の微粉末の混合比率が1〜5重量
%である、特許請求の範囲第(1)項記載の軟こう。
(2) The ointment according to claim (1), wherein the mixing ratio of the fine powder of the natural radioactive mineral is 1 to 5% by weight.
JP12388083A 1983-07-06 1983-07-06 Ointment Pending JPS6016928A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP12388083A JPS6016928A (en) 1983-07-06 1983-07-06 Ointment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12388083A JPS6016928A (en) 1983-07-06 1983-07-06 Ointment

Publications (1)

Publication Number Publication Date
JPS6016928A true JPS6016928A (en) 1985-01-28

Family

ID=14871648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP12388083A Pending JPS6016928A (en) 1983-07-06 1983-07-06 Ointment

Country Status (1)

Country Link
JP (1) JPS6016928A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6591081B2 (en) 2000-10-16 2003-07-08 Ricoh Company, Ltd. Fixing apparatus including toner releasing agent applying device and image forming apparatus including the same fixing apparatus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6591081B2 (en) 2000-10-16 2003-07-08 Ricoh Company, Ltd. Fixing apparatus including toner releasing agent applying device and image forming apparatus including the same fixing apparatus

Similar Documents

Publication Publication Date Title
GR1001503B (en) Method for the preparation of pharmaceutical compounds containing carbonic acids containing sulphur and the use thereof in fighting retroviruses.
ES2091441T3 (en) PHARMACEUTICAL COMPOSITION.
DE3774449D1 (en) PHARMACEUTICAL COMPOSITIONS.
RU95113862A (en) Pyrrolopyrimidine derivatives, pharmaceutical composition, intermediate compounds
BR9406363A (en) Pharmaceutical composition process for the preparation of the same use and process for the treatment of diseases related to gastric acid
EP0151989A3 (en) Means for the treatment of cardiac diseases
EE03105B1 (en) Formulations containing a pharmacologically ionizable active ingredient and the process for their preparation
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
IT1177863B (en) A GANGLIOSIDIC MIXTURE AS A THERAPEUTIC AGENT TO ELIMINATE PAIN IN PERIPHERAL NEUROPATHIES
ES478967A1 (en) 3,7-Disubstituted-3-cephem-4-carboxylic acid compounds
JPS6463522A (en) Pharmaceutical composition for treating and preventing gallstone and gall deficient indigestion
IT9067434A0 (en) PROCEDURE TO IMPROVE THE THERAPEUTIC EFFICACY OF LIPOSOLUBLE CORTICOSTEROIDS AND COMPOSITION FOR THE IMPLEMENTATION OF THIS PROCEDURE
PT95697A (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-ANDORGENICALLY ACTIVE SUBSTANCES
US3395236A (en) Composition comprising oleic acid, polyethylene glycol, and gelating for treating nail infections
ATE220912T1 (en) PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING ST1435 FOR TOPICAL USE
von KROGH Podophyllotoxin in serum: Absorption subsequent to three-day repeated applications of a 0.5% ethanolic preparation on condylomata acuminata
EP0242553A1 (en) Use of allantoin and sulfur in the manufacture of a medicament for the treatment of odontostomatologic diseases
JPS6016928A (en) Ointment
NO962129D0 (en) New pharmaceutical composition for the preparation of a stable powder containing an active principle comprising a compound of acetylsalicylic acid and metoclopramide
MX9307479A (en) USE OF CERTAIN DERIVATIVES OF METHANOBISPHOSPHONIC ACID IN FRACTURE HEALING.
DE60033830D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING COPPER, SALICYLIC ACID AND VITAMIN C
US3655881A (en) Method of treating burned skin
JPS6016921A (en) Plaster
DK277387A (en) THERAPEUTIC TOPICAL COMPOSITION AGAINST A HYPERPROLIFIING EPITHAL DISEASE
EG17992A (en) Preparation of a medicament for arthritis and theumatism